Oakwell Private Wealth Management LLC Makes New $377,000 Investment in Novo Nordisk A/S (NYSE:NVO)

Oakwell Private Wealth Management LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 3,649 shares of the company’s stock, valued at approximately $377,000.

Other large investors also recently made changes to their positions in the company. Jennison Associates LLC raised its position in shares of Novo Nordisk A/S by 100.3% in the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after buying an additional 11,727,507 shares during the period. FMR LLC raised its position in shares of Novo Nordisk A/S by 122.7% in the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock worth $1,098,328,000 after buying an additional 6,654,614 shares during the period. Morgan Stanley raised its position in shares of Novo Nordisk A/S by 96.5% in the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after buying an additional 4,526,199 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Novo Nordisk A/S by 91.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after buying an additional 4,350,862 shares during the period. Finally, Polen Capital Management LLC purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth $718,995,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NVO. UBS Group started coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. BMO Capital Markets began coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Stock Up 0.4 %

Shares of Novo Nordisk A/S stock traded up $0.53 during trading hours on Wednesday, hitting $128.84. 1,639,722 shares of the company’s stock traded hands, compared to its average volume of 4,760,968. The stock has a 50 day simple moving average of $127.05 and a 200-day simple moving average of $112.58. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market cap of $578.17 billion, a PE ratio of 47.62, a PEG ratio of 2.12 and a beta of 0.41. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.